These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27798112)

  • 21. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease.
    Nguyen M; Krainc D
    Proc Natl Acad Sci U S A; 2018 May; 115(21):5576-5581. PubMed ID: 29735704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A proteomic analysis of LRRK2 binding partners reveals interactions with multiple signaling components of the WNT/PCP pathway.
    Salašová A; Yokota C; Potěšil D; Zdráhal Z; Bryja V; Arenas E
    Mol Neurodegener; 2017 Jul; 12(1):54. PubMed ID: 28697798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.
    Lin CH; Lin HI; Chen ML; Lai TT; Cao LP; Farrer MJ; Wu RM; Chien CT
    Hum Mol Genet; 2016 May; 25(10):1965-1978. PubMed ID: 26931464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?
    Gillardon F
    J Neurochem; 2009 Sep; 110(5):1514-22. PubMed ID: 19545277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
    Harrison IF; Dexter DT
    Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration.
    Tsika E; Kannan M; Foo CS; Dikeman D; Glauser L; Gellhaar S; Galter D; Knott GW; Dawson TM; Dawson VL; Moore DJ
    Neurobiol Dis; 2014 Nov; 71():345-58. PubMed ID: 25174890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LRRK2 guides the actin cytoskeleton at growth cones together with ARHGEF7 and Tropomyosin 4.
    Häbig K; Gellhaar S; Heim B; Djuric V; Giesert F; Wurst W; Walter C; Hentrich T; Riess O; Bonin M
    Biochim Biophys Acta; 2013 Dec; 1832(12):2352-67. PubMed ID: 24075941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leucine-rich repeat kinase 2 phosphorylation on synapsin I regulates glutamate release at pre-synaptic sites.
    Marte A; Russo I; Rebosio C; Valente P; Belluzzi E; Pischedda F; Montani C; Lavarello C; Petretto A; Fedele E; Baldelli P; Benfenati F; Piccoli G; Greggio E; Onofri F
    J Neurochem; 2019 Aug; 150(3):264-281. PubMed ID: 31148170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1.
    Luerman GC; Nguyen C; Samaroo H; Loos P; Xi H; Hurtado-Lorenzo A; Needle E; Stephen Noell G; Galatsis P; Dunlop J; Geoghegan KF; Hirst WD
    J Neurochem; 2014 Feb; 128(4):561-76. PubMed ID: 24117733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell-autonomous role of leucine-rich repeat kinase in the protection of dopaminergic neuron survival.
    Kang J; Huang G; Ma L; Tong Y; Shahapal A; Chen P; Shen J
    Elife; 2024 Jun; 12():. PubMed ID: 38856715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NME1 Protects Against Neurotoxin-, α-Synuclein- and LRRK2-Induced Neurite Degeneration in Cell Models of Parkinson's Disease.
    Anantha J; Goulding SR; Tuboly E; O'Mahony AG; Moloney GM; Lomansey G; McCarthy CM; Collins LM; Sullivan AM; O'Keeffe GW
    Mol Neurobiol; 2022 Jan; 59(1):61-76. PubMed ID: 34623600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3β.
    Kawakami F; Shimada N; Ohta E; Kagiya G; Kawashima R; Maekawa T; Maruyama H; Ichikawa T
    FEBS J; 2014 Jan; 281(1):3-13. PubMed ID: 24165324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased Sirtuin Deacetylase Activity in LRRK2 G2019S iPSC-Derived Dopaminergic Neurons.
    Schwab AJ; Sison SL; Meade MR; Broniowska KA; Corbett JA; Ebert AD
    Stem Cell Reports; 2017 Dec; 9(6):1839-1852. PubMed ID: 29129681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CRISPR/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and α-Synuclein modulation in dopaminergic neurons.
    Qing X; Walter J; Jarazo J; Arias-Fuenzalida J; Hillje AL; Schwamborn JC
    Stem Cell Res; 2017 Oct; 24():44-50. PubMed ID: 28826027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice.
    Zhao Y; Keshiya S; Atashrazm F; Gao J; Ittner LM; Alessi DR; Halliday GM; Fu Y; Dzamko N
    Neurobiol Dis; 2018 Dec; 120():76-87. PubMed ID: 30194047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of TIR-1/SARM-1 by miR-71 Protects Dopaminergic Neurons in a
    Naidoo D; de Lencastre A
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease.
    De Miranda BR; Castro SL; Rocha EM; Bodle CR; Johnson KE; Greenamyre JT
    Neurobiol Dis; 2021 Jun; 153():105312. PubMed ID: 33636387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology.
    Fujimoto T; Kuwahara T; Eguchi T; Sakurai M; Komori T; Iwatsubo T
    Biochem Biophys Res Commun; 2018 Jan; 495(2):1708-1715. PubMed ID: 29223392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paraquat induces epigenetic changes by promoting histone acetylation in cell culture models of dopaminergic degeneration.
    Song C; Kanthasamy A; Jin H; Anantharam V; Kanthasamy AG
    Neurotoxicology; 2011 Oct; 32(5):586-95. PubMed ID: 21777615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition.
    Harrison IF; Smith AD; Dexter DT
    Neurosci Lett; 2018 Feb; 666():48-57. PubMed ID: 29273397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.